| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Department of Biology, The University of Texas at San Antonio, San Antonio, Texas,1 Departmento de Patología, Universidad de Valencia, Facultad de Medicina y Odontología, Valencia, Spain2
Received 18 July 2007/ Returned for modification 17 August 2007/ Accepted 17 October 2007
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
We have previously reported on the construction of a genetically engineered C. albicans strain (SSY50-B) in which NRG1 (a negative regulator of filamentation) was placed under the control of a tetracycline-regulatable promoter (21) and in which morphogenetic conversions can be controlled by the presence or absence of doxycycline (DOX). Using immunocompetent mice in a widely used murine model of hematogenously disseminated candidiasis, we have previously shown that, with this strain, mortality is achieved only when NRG1 expression is downregulated and morphogenetic conversions are allowed to occur (i.e., when the antibiotic is present in the drinking water) (21). To further examine the interplay between fungal dimorphism and host immune responses during C. albicans systemic infections, we have now used this strain to examine the pathogenic potential of yeast cell and filamentous forms in various inbred strains of mice with specific immune defects as well as in mice severely immunosuppressed by drug treatment and compared the outcomes with those in immunocompetent mice.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Animal experiments. Cultures of strain SSY50-B for injection were grown overnight at 25°C in YPD medium without DOX. Yeast cells were harvested by centrifugation and washed three times in sterile pyrogen-free saline. After cells were counted using a hemocytometer, dilutions were made to allow the appropriate number of yeast cells to be injected in a final volume of 200 µl into the lateral tail veins of 6- to 8-week-old female mice (five to eight mice per group). Confirmation of the number and viability of cells present in the infecting inocula was performed by plate count. Different mouse strains were used, including both BALB/c and C57BL/6 (both immunocompetent), and different immunodeficient strains including B-cell-deficient mice bearing a homozygous deletion of the igh locus (C.129B6-IgH-Jhdtm1Dhu), nude (T-cell-deficient mice; CANn.Cg-Foxn1nu/Crl), and SCID (lacking functional T and B cells; Prkdcscid) mice—all three in a BALB/c background—were used as well as DBA/2N mice, which are C5 deficient (a component of the complement pathway) and are considered to have impaired neutrophil activity (1, 2, 11, 27). We also tested the impact of the yeast cell and filamentous forms in BALB/c mice severely immunosuppressed through cyclophosphamide-cortisone acetate treatment (CPM-treated mice). Briefly, injections of cyclophosphamide (200 mg/kg of body weight, intraperitoneally) and cortisone acetate (250 mg/kg, subcutaneously) were administered on days 4 and 1 prior to infection. For each different mouse strain, two groups were injected: one group of mice did not receive DOX in their drinking water whereas the other group of mice received 2 mg/ml DOX in their water, starting 3 days prior to infection. Mice were monitored for survival for 21 days postinfection. Days on which mice died were recorded; moribund animals were euthanized and recorded as dying the following day. BALB/c, nude, SCID, C57BL/6, and DBA/2N mice were obtained from the National Cancer Institute (Bethesda, MD). B-cell-deficient mice were obtained from Taconic Farms (Germantown, NY).
For all animals, upon death or sacrifice, kidneys were removed for the determination of fungal burden and histology. Briefly, kidneys for histological analysis were fixed in 10% buffered formalin and embedded in paraffin, and thin tissue slices were removed and stained with Grocott-Gomori methenamine-silver to visualize fungal elements present in tissues and with hematoxylin and eosin to evaluate necrosis and inflammation. Cell counts were determined by weighing and homogenizing the kidneys and then plating samples onto solid YPD medium to determine the number of viable CFU. All animal experiments were performed in accordance with institutional regulations. After the mice were received, they were allowed a 1-week acclimatization period before experiments were started.
Statistical analyses. Survival data and differences between groups were analyzed using the Kaplan-Meier log rank test. Organ fungal burdens were monitored by determining the total number of CFU per gram of tissue in kidney. Thereafter, logarithmic values for the different groups were obtained, and results were expressed as geometric means and standard deviations. A Mann-Whitney test was used to determine statistical significance for differences in CFU data. Analyses were performed using GraphPad Prism, version 4.00, for Windows (San Diego, CA).
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
|
Fungal burden, fungal morphology, and histopathological findings in kidney tissues of animal hosts with disseminated candidiasis. Since the kidney represents the main target organ in this model of hematogenously disseminated candidiasis, we determined the CFU counts in the kidneys recovered from the different groups of mice at time of death (Table 1). For most mouse strains and treatment groups, tissue burdens were essentially identical to those observed using immunocompetent BALB/c mice, with the exception of DBA/2N mice, which displayed slightly lower organ loads (P = 0.0109), probably a reflection of their increased susceptibility to candidiasis and also of the fact that all deaths in this group occurred very early within the first 24 h postinfection. Also, the CPM-treated mice infected in the absence of DOX exhibited higher fungal loads than both BALB/c (P = 0.0303) and CPM-treated mice in the presence of antibiotic (P = 0.0087), although the increased plating efficiency of yeast cell forms versus their filamentous counterparts may have contributed to these minor differences. We also observed that significant fungal bioburdens were maintained throughout the course of the infection in all of the mouse strains even in the absence of DOX, as detected in animals sacrificed at the end of the experimental period (21 days) (data not shown).
|
|
|
Overall, the results presented here reaffirm that the C. albicans tet-NRG1 strain represents a powerful tool to investigate different aspects of C. albicans pathogenesis. They also highlight the importance of properly integrating and taking into account the interplay between host immunity and mechanisms of fungal virulence, an area which has been largely overlooked in the study of C. albicans pathogenesis, as we try to better understand the clinical scenario in patients suffering from these insidious infections.
| ACKNOWLEDGMENTS |
|---|
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases or the National Institutes of Health.
| FOOTNOTES |
|---|
Published ahead of print on 29 October 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
| 1. | Ashman, R. B., and J. M. Papadimitriou. 1987. Murine candidiasis. Pathogenesis and host responses in genetically distinct inbred mice. Immunol. Cell Biol. 65:163-171.[CrossRef] |
| 2. | Ashman, R. B., J. M. Papadimitriou, A. Fulurija, K. E. Drysdale, C. S. Farah, O. Naidoo, and T. Gotjamanos. 2003. Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb. Pathog. 34:103-113.[CrossRef][Medline] |
| 3. | Balish, E., J. Jensen, T. Warner, J. Brekke, and B. Leonard. 1993. Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J. Med. Vet. Mycol. 31:143-154.[Medline] |
| 4. | Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. R. Edwards, J. Tolson, T. Henderson, and W. J. Martone. 1991. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am. J. Med. 91:86S-89S.[Medline] |
| 5. | Beck-Sague, C., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.[Medline] |
| 6. | Calderone, R. A., and W. A. Fonzi. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9:327-335.[CrossRef][Medline] |
| 7. | Casadevall, A., and L. Pirofski. 2001. Host-pathogen interactions: the attributes of virulence. J. Infect. Dis. 184:337-344.[CrossRef][Medline] |
| 8. | Casadevall, A., and L. A. Pirofski. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67:3703-3713. |
| 9. | Casadevall, A., and L. A. Pirofski. 2003 Microbial virulence results from the interaction between host and microorganism. Trends Microbiol. 11:157-158. (Author reply, 11:158-159.)[CrossRef][Medline] |
| 10. | Casadevall, A., and L. A. Pirofski. 2002. What is a pathogen? Ann. Med. 34:2-4.[CrossRef][Medline] |
| 11. | Cinader, B., S. Dubiski, and A. C. Wardlaw. 1966. Genetics of MuB1 and of a complement defect in inbred strains of mice. Genet. Res. 7:32-43.[Medline] |
| 12. | Cutler, J. E. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187-218.[CrossRef][Medline] |
| 13. | Lee, K. W., and E. Balish. 1981. Systemic candidosis in germfree, flora-defined and conventional nude and thymus-bearing mice. J. Reticuloendothel. Soc. 29:71-77.[Medline] |
| 14. | Levitz, S. M. 1992. Overview of host defenses in fungal infections. Clin. Infect. Dis. 14(Suppl. 1):S37-S42.[Medline] |
| 15. | Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90:939-949.[CrossRef][Medline] |
| 16. | Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163. |
| 17. | Romani, L. 2004. Immunity to fungal infections. Nat. Rev. Immunol. 4:1-23.[CrossRef][Medline] |
| 18. | Romani, L. 2000. Innate and adaptive immunity in Candida albicans infections and saprophytism. J. Leukoc. Biol. 68:175-179. |
| 19. | Rooney, P. J., and B. S. Klein. 2002. Linking fungal morphogenesis with virulence. Cell Microbiol. 4:127-137.[CrossRef][Medline] |
| 20. | Saville, S. P., A. L. Lazzell, A. P. Bryant, A. Fretzen, A. Monreal, E. O. Solberg, C. Monteagudo, J. L. Lopez-Ribot, and G. T. Milne. 2006. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob. Agents Chemother. 50:3312-3316. |
| 21. | Saville, S. P., A. L. Lazzell, C. Monteagudo, and J. L. Lopez-Ribot. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot. Cell 2:1053-1060. |
| 22. | Sheppard, D. C., G. Rieg, L. Y. Chiang, S. G. Filler, J. E. Edwards, Jr., and A. S. Ibrahim. 2004. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 48:1908-1911. |
| 23. | Shoham, S., and S. M. Levitz. 2005. The immune response to fungal infections. Br. J. Haematol. 129:569-582.[CrossRef][Medline] |
| 24. | Stephens-Romero, S. D., A. J. Mednick, and M. Feldmesser. 2005. The pathogenesis of fatal outcome in murine pulmonary aspergillosis depends on the neutrophil depletion strategy. Infect. Immun. 73:114-125. |
| 25. | Vespa, M. N., J. L. Lopez-Ribot, and W. L. Chaffin. 1995. Adherence of germ tubes of Candida albicans to tissues from immunocompromised mice. FEMS Immunol. Med. Microbiol. 11:57-63.[CrossRef][Medline] |
| 26. | Viudes, A., J. Peman, E. Canton, P. Ubeda, J. L. Lopez-Ribot, and M. Gobernado. 2002. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur. J. Clin. Microbiol. Infect. Dis. 21:767-774.[CrossRef][Medline] |
| 27. | Wetsel, R. A., D. T. Fleischer, and D. L. Haviland. 1990. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J. Biol. Chem. 265:2435-2440. |
| 28. | Wey, S. B., M. Mori, M. A. Pfaller, R. F. Woolson, and R. P. Wenzel. 1988. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch. Intern. Med. 148:2642-2645.[Abstract] |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|